Repligen Corporation

NasdaqGS:RGEN Stock Report

Market Cap: US$9.0b

Repligen Valuation

Is RGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RGEN ($158.14) is trading below our estimate of fair value ($216.39)

Significantly Below Fair Value: RGEN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGEN?

Key metric: As RGEN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RGEN. This is calculated by dividing RGEN's market cap by their current revenue.
What is RGEN's PS Ratio?
PS Ratio14x
SalesUS$633.51m
Market CapUS$9.02b

Price to Sales Ratio vs Peers

How does RGEN's PS Ratio compare to its peers?

The above table shows the PS ratio for RGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.5x
BIO Bio-Rad Laboratories
3.7x3.6%US$9.6b
QGEN Qiagen
5.1x7.3%US$10.1b
CRL Charles River Laboratories International
2.4x4.4%US$9.7b
BRKR Bruker
2.7x7.1%US$8.7b
RGEN Repligen
14x12.9%US$9.0b

Price-To-Sales vs Peers: RGEN is expensive based on its Price-To-Sales Ratio (14x) compared to the peer average (3.5x).

Price to Sales Ratio vs Industry

How does RGEN's PS Ratio compare vs other companies in the US Life Sciences Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x2.4%US$1.82b
ATLN Atlantic International
0.6xn/aUS$270.79m
NOTV Inotiv
0.3x6.0%US$151.15m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
RGEN 14.0xIndustry Avg. 3.3xNo. of Companies9PS02.85.68.411.214+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RGEN is expensive based on its Price-To-Sales Ratio (14x) compared to the US Life Sciences industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is RGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14x
Fair PS Ratio5.9x

Price-To-Sales vs Fair Ratio: RGEN is expensive based on its Price-To-Sales Ratio (14x) compared to the estimated Fair Price-To-Sales Ratio (5.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RGEN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$158.14
US$190.31
+20.3%
10.3%US$225.00US$160.00n/a13
Dec ’25US$150.54
US$192.25
+27.7%
9.8%US$225.00US$160.00n/a12
Nov ’25US$138.61
US$191.83
+38.4%
9.8%US$225.00US$160.00n/a12
Oct ’25US$145.74
US$192.67
+32.2%
9.9%US$225.00US$160.00n/a12
Sep ’25US$150.93
US$192.45
+27.5%
9.9%US$225.00US$160.00n/a11
Aug ’25US$165.67
US$193.70
+16.9%
10.1%US$225.00US$160.00n/a10
Jul ’25US$123.32
US$198.62
+61.1%
10.6%US$225.00US$155.00n/a11
Jun ’25US$149.09
US$204.16
+36.9%
8.2%US$225.00US$170.00n/a11
May ’25US$158.36
US$206.58
+30.4%
8.9%US$225.00US$170.00n/a10
Apr ’25US$182.95
US$210.89
+15.3%
8.1%US$230.00US$180.00n/a11
Mar ’25US$195.52
US$210.89
+7.9%
8.1%US$230.00US$180.00n/a11
Feb ’25US$192.71
US$189.71
-1.6%
10.5%US$211.00US$148.00n/a11
Jan ’25US$179.80
US$182.00
+1.2%
10.8%US$211.00US$148.00n/a12
Dec ’24US$164.94
US$171.38
+3.9%
9.7%US$210.00US$148.00US$150.5413
Nov ’24US$131.46
US$175.46
+33.5%
9.7%US$210.00US$148.00US$138.6113
Oct ’24US$159.01
US$197.62
+24.3%
8.5%US$240.00US$165.00US$145.7413
Sep ’24US$175.74
US$197.62
+12.4%
8.5%US$240.00US$165.00US$150.9313
Aug ’24US$167.12
US$197.92
+18.4%
13.5%US$250.00US$157.00US$165.6713
Jul ’24US$141.46
US$201.50
+42.4%
13.3%US$250.00US$157.00US$123.3212
Jun ’24US$167.07
US$202.33
+21.1%
13.3%US$250.00US$157.00US$149.0912
May ’24US$153.54
US$215.42
+40.3%
11.7%US$250.00US$170.00US$158.3612
Apr ’24US$168.36
US$215.58
+28.0%
11.5%US$250.00US$172.00US$182.9512
Mar ’24US$176.37
US$214.27
+21.5%
11.9%US$250.00US$172.00US$195.5211
Feb ’24US$190.79
US$224.55
+17.7%
13.5%US$270.00US$179.00US$192.7111
Jan ’24US$169.31
US$228.27
+34.8%
12.1%US$270.00US$180.00US$179.8011
Dec ’23US$188.17
US$237.89
+26.4%
8.7%US$270.00US$200.00US$164.949

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 23:55
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Repligen Corporation is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
Hugo SolvetBNP Paribas Exane
Kyle MiksonCanaccord Genuity